Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;78(5):1269-1279.
doi: 10.1111/all.15585. Epub 2022 Dec 3.

Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

Dorothea Terhorst-Molawi  1   2 , Tomasz Hawro  3 , Eva Grekowitz  1   2 , Lea Kiefer  1   2 , Kunal Merchant  4 , Diego Alvarado  4 , Lawrence J Thomas  4 , Thomas Hawthorne  4 , Elizabeth Crowley  4 , Margo Heath-Chiozzi  4 , Martin Metz  1   2 , Marcus Maurer  1   2
Affiliations

Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

Dorothea Terhorst-Molawi et al. Allergy. 2023 May.

Abstract

Background: Chronic inducible urticaria (CIndU) is characterized by mast cell (MC)-mediated wheals in response to triggers: cold in cold urticaria (ColdU) and friction in symptomatic dermographism (SD). KIT receptor activation by stem cell factor (SCF) is essential for MC function. Barzolvolimab (CDX-0159) is a humanized antibody that inhibits KIT activation by SCF and was well tolerated in healthy volunteers with dose-dependent plasma tryptase suppression indicative of systemic mast cell ablation.

Methods: This is an open-label, trial in patients with antihistamine refractory ColdU or SD, receiving one IV dose of barzolvolimab (3 mg/kg), with a 12-week follow-up. Primary endpoint was safety/tolerability; pharmacodynamic (PD)/clinical endpoints included serum tryptase, plasma SCF, skin MC histology, provocation tests, urticaria control test (UCT), and dermatology life quality index (DLQI).

Results: Analysis populations were safety (n = 21) and pharmacodynamics/clinical activity (n = 20). Barzolvolimab was well tolerated; most adverse events were mild and resolved. Treatment resulted in significant depletion of skin MCs, decreased tryptase (<limit of detection), and increased soluble SCF through Week 12. Complete responses (negative provocation test) occurred in 95% (n = 19/20) of patients (n = 10/10 ColdU; n = 9/10 SD), and all (n = 20/20) showed improvement in urticaria control (UCT ≥ 12). The kinetics of clinical activity mirrored that of MC and tryptase reduction. DLQI-measured impairment significantly decreased to minimal/none in 93% of patients on study.

Conclusion: In CIndU patients, barzolvolimab was well tolerated, demonstrated marked, rapid, durable depletion of skin MCs, circulating tryptase, and reductions in clinical activity with significant improvements in disease control and quality of life (QoL) demonstrating potential therapeutic effects for MC-mediated disorders.

Keywords: CDX-0159; barzolvolimab; chronic inducible urticaria; cold urticaria; symptomatic dermographism.

PubMed Disclaimer

References

REFERENCES

    1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2022;77(3):734-766.
    1. Dressler C, Rosumeck S, Werner RN, et al. Executive summary of the methods report for ‘The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update’. Allergy. 2018;73(5):1145-1146.
    1. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119-1130.
    1. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802.
    1. Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options. J Allergy Clin Immunol Pract. 2020;8(9):3141-3161.

Publication types

LinkOut - more resources